Clinical Trials

25 enrolled

Penile Squamous Cell Carcinoma (PSCC)

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

240 enrolled

Muscle-invasive Bladder Cancer

NCT06011954 2026-04-14

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting

202 enrolled

Urinary Bladder Neoplasms

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT06311214 2026-04-13

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07232602 2026-04-13

MK-3475-04D

55 enrolled

Urinary Bladder Neoplasms

NCT07421700 2026-04-07

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

132 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07484022 2026-04-07

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Recruiting

37 enrolled

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT05614739 2026-03-23

FORAGER-1

Phase 1 Recruiting

535 enrolled

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT06891560 2026-03-20

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

34 enrolled

Carcinoma, Adenoid Cystic

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT06862219 2026-03-06

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

100 enrolled

Carcinoma, Transitional Cell

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

41 enrolled

Advanced Bladder Cancer

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

47 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

47 enrolled

Urinary Bladder Neoplasms

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

24 enrolled

Carcinoma, Transitional Cell

NCT06724159 2026-02-17

SOGUG-PRINCIS

Recruiting

500 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

21 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04878029 2026-01-23

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Recruiting

32 enrolled

Carcinoma, Transitional Cell

NCT06041503 2026-01-23

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

68 enrolled

Adenocarcinoma of the Bladder

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

20 enrolled

Urinary Bladder Neoplasms

NCT06104618 2025-12-11

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

28 enrolled

Penile Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

70 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06906822 2025-09-18

PlugIN

60 enrolled

Dermatologic

Melanoma

NCT06394570 2025-09-15

STAR-EV

19 enrolled

Urinary Bladder Neoplasms

NCT06302569 2025-09-09

REPRINT

23 enrolled

Carcinoma, Renal Cell

NCT05879653 2025-08-29

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

30 enrolled

Urinary Bladder Neoplasms

NCT06356155 2025-07-29

NEPTUNE

32 enrolled

Carcinoma, Transitional Cell

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

25 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

700 enrolled